These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 22143340)

  • 41. Effective etanercept treatment for psoriatic arthritis complicating concomitant human immunodeficiency virus and hepatitis C virus infection.
    Linardaki G; Katsarou O; Ioannidou P; Karafoulidou A; Boki K
    J Rheumatol; 2007 Jun; 34(6):1353-5. PubMed ID: 17552060
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease.
    Cepeda EJ; Williams FM; Ishimori ML; Weisman MH; Reveille JD
    Ann Rheum Dis; 2008 May; 67(5):710-2. PubMed ID: 18079191
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical and economic impact of the use of etanercept 25 mg once weekly in rheumatoid arthritis, psoriatic arthropathy and ankylosing spondylitis patients.
    Borrás-Blasco J; Gracia-Pérez A; Rosique-Robles JD; Casterá ME; Abad FJ
    Expert Opin Biol Ther; 2014 Feb; 14(2):145-50. PubMed ID: 24359492
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Case of coexisting psoriatic arthritis and bullous pemphigoid improved by etanercept.
    Nin M; Tokunaga D; Ishii N; Komai A; Hashimoto T; Katoh N
    J Dermatol; 2013 Jan; 40(1):55-6. PubMed ID: 22963138
    [No Abstract]   [Full Text] [Related]  

  • 45. Etanercept plus ciclosporin versus etanercept plus methotrexate for maintaining clinical control over psoriatic arthritis: a randomised pilot study.
    Atzeni F; Boccassini L; Antivalle M; Salaffi F; Sarzi-Puttini P
    Ann Rheum Dis; 2011 Apr; 70(4):712-4. PubMed ID: 20810394
    [No Abstract]   [Full Text] [Related]  

  • 46. Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor alpha inhibitors.
    Deng A; Harvey V; Sina B; Strobel D; Badros A; Junkins-Hopkins JM; Samuels A; Oghilikhan M; Gaspari A
    Arch Dermatol; 2006 Feb; 142(2):198-202. PubMed ID: 16490847
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: report of 3 cases.
    Magliocco MA; Gottlieb AB
    J Am Acad Dermatol; 2004 Oct; 51(4):580-4. PubMed ID: 15389194
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and safety of etanercept in chronic immune-mediated disease.
    Murdaca G; Spanò F; Contatore M; Guastalla A; Magnani O; Puppo F
    Expert Opin Drug Saf; 2014 May; 13(5):649-61. PubMed ID: 24654562
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hepatotoxicity associated with etanercept in psoriatic arthritis.
    Leak AM; Rincon-Aznar B
    J Rheumatol; 2008 Nov; 35(11):2286-7. PubMed ID: 19004062
    [No Abstract]   [Full Text] [Related]  

  • 50. Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis.
    Finckh A; Simard JF; Gabay C; Guerne PA;
    Ann Rheum Dis; 2006 Jun; 65(6):746-52. PubMed ID: 16339288
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Role of Agents other than Tumor Necrosis Factor Blockers in the Treatment of Psoriatic Arthritis.
    Atzeni F; Costa L; Caso F; Scarpa R; Sarzi-Puttini P
    J Rheumatol Suppl; 2015 Nov; 93():79-81. PubMed ID: 26523064
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Etanercept therapy for psoriatic arthritis in the presence of recurrent non-Hodgkin lymphoma.
    Pai S; Rosenstein ED; Kramer N
    J Clin Rheumatol; 2012 Sep; 18(6):301-3. PubMed ID: 22955480
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Indications and adverse events with the use of anti-TNFalpha agents in pediatric rheumatology: experience of a single center].
    de Oliveira SK; de Almeida RG; Fonseca AR; Rodrigues MC; Sztajnbok F; Diniz C
    Acta Reumatol Port; 2007; 32(2):139-50. PubMed ID: 17572652
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy of etanercept in lymphedema associated with psoriatic arthritis.
    Lekpa FK; Economu-Dubosc A; Fevre C; Claudepierre P; Chevalier X
    J Rheumatol; 2009 Jan; 36(1):207-8. PubMed ID: 19208540
    [No Abstract]   [Full Text] [Related]  

  • 55. Etanercept injection site reaction.
    Clelland S; Hunek JR
    Dermatol Nurs; 2005 Oct; 17(5):375-. PubMed ID: 16294944
    [No Abstract]   [Full Text] [Related]  

  • 56. Juvenile psoriatic arthritis and acquired sensorineural hearing loss in a teenager: is there an association?
    Giani T; Simonini G; Lunardi C; Puccetti A; De Martino M; Falcini F
    Clin Exp Rheumatol; 2006; 24(3):344-6. PubMed ID: 16870107
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A case of Brucella spondylitis in a patient with psoriatic arthritis receiving infliximab.
    Papagoras CE; Argyropoulou MI; Voulgari PV; Vrabie I; Zikou AK; Drosos AA
    Clin Exp Rheumatol; 2009; 27(1):124-7. PubMed ID: 19327241
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immunomodulating drugs in the management of psoriatic arthritis.
    Jackson CG
    Am J Clin Dermatol; 2001; 2(6):367-75. PubMed ID: 11770391
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Predominant cervical involvement in patients with psoriatic arthritis: report of two cases.
    Ouédraogo DD; Palazzo E; Nlomé-Nzé M; Somogyi N; Ballard M; Hayem G; Meyer O
    Joint Bone Spine; 2007 Mar; 74(2):175-8. PubMed ID: 16987680
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cyclosporine in psoriatic arthropathy.
    Soriano A; Pipitone N; Salvarani C
    Clin Exp Rheumatol; 2015; 33(5 Suppl 93):S101-3. PubMed ID: 26470797
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.